Senseonics Holdings, Inc. (SENS)
NYSEAMERICAN: SENS · Real-Time Price · USD
0.317
-0.001 (-0.31%)
At close: Nov 20, 2024, 4:00 PM
0.320
+0.003 (0.91%)
After-hours: Nov 20, 2024, 7:56 PM EST

Company Description

Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.

The company’s products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.

Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Senseonics Holdings, Inc.
Senseonics Holdings logo
Country United States
Founded 1996
Industry Medical Devices
Sector Healthcare
Employees 132
CEO Timothy Goodnow

Contact Details

Address:
20451 Seneca Meadows Parkway
Germantown, Maryland 20876-7005
United States
Phone 301 515 7260
Website senseonics.com

Stock Details

Ticker Symbol SENS
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001616543
CUSIP Number 81727U105
ISIN Number US81727U1051
Employer ID 47-1210911
SIC Code 3823

Key Executives

Name Position
Dr. Timothy T. Goodnow Ph.D. President, Chief Executive Officer and Director
Dr. Mukul Jain Ph.D. Chief Operating Officer
Dr. Francine Ratner Kaufman M.D. Chief Medical Officer and Director

Latest SEC Filings

Date Type Title
Nov 19, 2024 8-K Current Report
Nov 19, 2024 PRE 14A Other preliminary proxy statements
Nov 8, 2024 D Notice of Exempt Offering of Securities
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Oct 28, 2024 8-K Current Report
Oct 28, 2024 424B5 Filing
Oct 25, 2024 424B5 Filing
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report